Keywords: orion, stalevo, fails, delay, dyskinesia, early, pd
Orion's Stalevo fails to delay dyskinesia in early PD trial
Article | 02 March 2009
Orion's Stalevo (levodopa, carbidopa and entacapone) missed the primary endpoint in a trial of 747 patients with early Parkinson's disease requiring ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
